Healthcare / BiotechnologyNasdaqGS
$8.08
-0.28 (-3.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-59.7M · quality 71.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$440M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.2%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+33.0%
FCF CAGR
—
FCF margin
-4675.5%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.9M · net income $-143.4M · FCF $-133.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.9M | $2.9M | $2.4M | $2.4M | $1.2M |
| Net Income | $-143.4M | $-143.4M | $-62.8M | $-20.5M | $-23.9M |
| EBITDA | $-160.2M | $-160.2M | $-77.7M | $-40.1M | $-23.9M |
| EPS | -2.66 | -2.66 | -1.17 | -1.05 | -0.66 |
| Operating Margin | -5618.8% | -5618.8% | -3281.2% | -1685.5% | -1972.7% |
| Net Margin | -5026.0% | -5026.0% | -2650.0% | -862.9% | -1969.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Current Ratio | 23.14 | 23.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-133.4M | $-133.4M | $-59.7M | $-38.1M | $-19.1M |
| Returns | |||||
| ROE | -42.2% | -42.2% | -13.4% | 16.7% | 22.5% |
| Valuation | |||||
| P/B | 1.28 | 1.28 | 2.09 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 20.4% | 20.4% | -0.4% | 96.4% | — |
| EPS Growth | -127.0% | -127.0% | -11.3% | -60.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.17 → -2.66
Residual
-12.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.